glp-1 receptor agonist with dpp-4 inhibitor combination not recommended Clinical Use of Inhibitors Insights into the Roles of

However, evidence specifically addressing their use in SIH and SID remains limited, underscoring the need for focussed investigation in this patient population

A head-to-head review of clinical studies determined that among available GLP-1 RAs, there were A1C reductions from 0.78% to 1.9%

While pancreatitis remains a warning on product labeling and a theoretical concern due to shared pathways, large-scale CVOTs and subsequent meta-analyses have not shown a statistically significant increase in the risk of acute pancreatitis compared to placebo [86]

Yellow Card Report a side effect or safety concern

P = 0.002) compared with placebo (Figure 2A)

While all of these potential benefits are exciting, experts said they need much more study, and even then, whether they might ever be utilized as a treatment for schizophrenia, for example, would depend on a number of factors: how much and how consistently they work, as well as how they compare to treatments that are already available